admixor@126.com +86 177 5921 5460 Reply within 1 business day
Fine ChemicalsHistoric: 2019–2025Forecast: 2026–2033

Pharma Intermediates and CDMO Custom Synthesis

Outsourcing demand and capacity structure as molecules get harder

2025
Base year
2019–2025
Historic
2026–2033
Forecast
4
Regions
4
Segments
PDF / Excel / PPT
Formats
Semi-annual
Update

Abstract

This report covers the highest-value downstream of fine chemicals: pharma intermediates and custom synthesis (CDMO). It spans innovator intermediates, specialty APIs, peptide and oligonucleotide building blocks, and pharmaceutical excipients, and analyses the changing split between captive and merchant production.

The central judgement is that the moat has moved from capacity to quality systems and process development. Being selected as a supplier during early clinical phases locks in commercial-scale volume later, which makes the front-end process team more decisive than back-end reactor volume.

Sources

  • A The Business Research Company《CDMO Global Market Report》:2025 年 2,747.9 亿美元、2030 年 5,038.2 亿美元、CAGR 12.9%。https://www.thebusinessresearchcompany.com/report/contract-development-manufacturing-organizations-global-market-report(2026-11 访问)
  • B MarketsandMarkets《Pharmaceutical Contract Manufacturing》:2025 年 2,099.0 亿美元、2030 年 3,119.5 亿美元、CAGR 8.2%。https://www.marketsandmarkets.com/Market-Reports/pharmaceutical-contract-manufacturing-market-201524381.html(2026-11 访问)
  • C Grand View Research《Pharmaceutical CDMO Market》:2025 年 1,660.0 亿美元、2026 年 1,776.0 亿美元、2033 年 2,936.0 亿美元、CAGR 7.4%。https://www.grandviewresearch.com/industry-analysis/pharmaceutical-cdmo-market-report(2026-11 访问)
  • D PW Consulting《Worldwide Pharmaceutical Intermediate CDMO》:2032 年 633.3 亿美元、CAGR 8.56%(中间体口径)。https://pmarketresearch.com/worldwide-pharmaceutical-intermediate-cdmo-market-research/(2026-11 访问)
  • E 下游结构占比:Future Market Insights《Fine Chemicals Market》2026 年预测。https://www.futuremarketinsights.com/reports/fine-chemicals-market(2026-11 访问)
  • F 供应商准入与路径依赖:行业公开访谈与质量体系要求(ICH Q7 / Q10、EHS 审计)定性汇总。

Key findings

  • Total-scope CDMO was about USD 274.79 billion in 2025, reaching USD 503.82 billion by 2030 at a 12.9% CAGR (The Business Research Company); pharmaceutical contract manufacturing was USD 209.90 billion in 2025 and USD 311.95 billion by 2030, a 8.2% CAGR (MarketsandMarkets).
  • The scopes are huge and not interchangeable: Grand View Research puts pharmaceutical CDMO at USD 166.0 billion in 2025, about 60% of total-scope CDMO, while intermediate custom synthesis is only USD 63.33 billion by 2032 (PW Consulting).
  • Pharma and nutraceuticals are the largest fine chemicals downstream — APIs about 48% of 2026 product-type sales and specialty intermediates ~17% (Future Market Insights forecast).
  • Rising molecular complexity keeps pushing outsourcing ratios higher, and new modalities such as peptides and oligonucleotides create structural demand for high-purity building blocks and dedicated capacity.
  • Supplier choice is strongly path-dependent: replacing an early-clinical supplier at commercial scale is prohibitively costly, and quality systems, EHS records and audit pass rates are harder gates than capacity.

How to obtain

From ¥199 (introductory, first 100 buyers). Available as a single report, by chapter or as an annual subscription; the final quote follows the scope you select. We reply within one business day.

Sector overview

Delivery

  • PDF:Research brief, 5 pages (abstract, key findings, cross-source table, scope and players)
  • Excel:Data pack and chart source data (tables and original rows)
  • PPT:Management summary (selected reports)

CDMO and pharma contract manufacturing: definitions compared

Total-scope CDMO, pharma contract manufacturing and intermediate custom synthesis are three different scopes and cannot be added or averaged.

Source and scopeBase-year sizeForecast yearForecast sizeCAGR
The Business Research Company(CDMO 全口径)2,747.9 亿美元 (2025)20305,038.2 亿美元12.9%
MarketsandMarkets(医药合同生产)2,099.0 亿美元 (2025)20303,119.5 亿美元8.2%
Grand View Research(医药 CDMO)1,660.0 亿美元 (2025)20332,936.0 亿美元7.4%
PW Consulting(中间体定制合成)—2032633.3 亿美元8.56%

Source: 各机构公开发布摘要,2025–2026

Scope — Regions

  • China
  • India
  • Europe
  • North America

Scope — Main participants

  • Lonza
  • Evonik
  • BASF
  • Merck KGaA
  • Johnson Matthey
  • 药明康德系 / WuXi
  • 九洲药业
  • 普洛药业

Table of contents

This outline is a roadmap: the brief delivered today is 5 pages — abstract, key findings, cross-source table, and scope/players. The chapters below are not in the current brief; they are candidates for chapter purchase or an annual subscription.

  1. 1. Scope: intermediates, APIs, building blocks and excipients
  2. 2. Global market size and outsourcing ratio
  3. 3. Captive versus merchant production structure
  4. 4. New modalities: peptide and oligonucleotide building blocks
  5. 5. Process routes: continuous flow, biocatalysis, green chemistry
  6. 6. Supplier selection and switching costs
  7. 7. Capacity footprint: China, India, Europe, North America
  8. 8. Quality systems and regulatory compliance
  9. 9. CDMO company profiles
  10. 10. Risks: customer concentration, geopolitics, pricing pressure

Related reports

Get this report

Start with the free sample to check the structure and the methodology; for the full edition fill in the form and you will get a quote and payment details within one business day.

Download sample (PDF, free)
Single report ¥199 (founding, first 100) / ¥999 (standard); one report carries one price at a time, and chapter or subscription terms can work out better.

Single report ¥199 (founding, first 100) / ¥999 (standard); one report carries one price at a time, and chapter or subscription terms can work out better.

Your details go straight to the research team's inbox and are used only to answer this request.

Cannot find your segment?

Tell us the product, geography and metrics you care about. We will scope size, growth and players to your definition and deliver research you can drop straight into a project file.